Trial Profile
A Phase I, Open-Label Study to Investigate the Regional Bioavailability of ABT-333 When Delivered to Different Sites Within the Gastrointestinal Tract in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2014
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors AbbVie
- 10 Mar 2014 New trial record